




WESLEY MEDICAL RESEARCH.

THE WESLEY HOSPITAL | ST. ANDREW'S HOSPITAL
BUDERIM PRIVATE HOSPITAL | ST. STEPHEN'S HOSPITAL

2018-2019 Annual Report

*Giving hope and
changing lives.*



Feedback is important
for improving the value of
our future annual reports.

We welcome your comments
which can be made by
contacting us at:

Wesley Medical Research
ABN 85 066 149 666

Street Address

Level 8, East Wing, The Wesley Hospital
451 Coronation Drive, Auchenflower
QLD 4066

Postal Address

PO Box 499, Toowong DC 4066

Phone

07 3721 1500

**Incorporation and
Charity Status**

Tax Concessions and Fundraising
– Health Promotion Charity registered by
the Australian Tax Office (ATO) as:

- A Deductible Gift Recipient (DGR)
- An income tax exempt charity (holding tax concessions and exemptions relating to income, goods and services and fringe benefit taxes)

Contents

4	Organisation	15	Research Projects
6	Highlights	21	Thank you
8	Chairman & Chief Research Advisor's report	24	Board
10	Impact	26	Managing resources
14	Research Program		

Wesley Medical Research

Established in 1994,
Wesley Medical Research
is Queensland's second
oldest medical research
organisation.

WHO WE ARE

Founded by UnitingCare, the research activity undertaken by Wesley Medical Research specifically aims to span all UnitingCare hospitals including The Wesley Hospital, St Andrew's War Memorial Hospital, Buderim Private Hospital at the Sunshine Coast, and St Stephen's Hospital at Hervey Bay.

Wesley Medical Research houses a world-class biobank which sources, stores and supplies tissue, blood and data for collaboration with Australian and international biomedical researchers.

In addition to our hospital remit, Wesley Medical Research is focused on improving health in rural and remote communities such as the Bowen Basin.

From the beginning, Wesley Medical Research has encouraged and supported research initiated by people who really know the value of clinical research - practising doctors, nurses and allied health professionals in our hospitals. They are driven by a desire to give patients better treatment options and improved quality of life for a range of contemporary diseases and health issues.

OUR MISSION

Immediate improvements in patient care and quality of life through applied medical research.

OUR VISION

A world leader in applied medical research acknowledged for achieving excellence and innovation in patient care. Wesley Medical Research fosters a strong research culture in UnitingCare Health hospitals, improving patient outcomes by linking medical research and clinical practice.

 EMERALD



HERVEY BAY 


BUDERIM 

BRISBANE 



They are driven by a desire to give patients better treatment options and improved quality of life.

Our philosophy



PATIENTS ARE OUR FOCUS

We empower change at the front line, giving clinicians the opportunity to be curious, to ask questions and challenge the status quo. We work with people to seek answers to improve their quality of life, outcome or prognosis.

WE VALUE TIME


Where a cure is years away, we give patients options today. Our point of difference is that we bring together patients, clinicians and research with the aim of delivering results that don't just help our community, but change the world.

Highlights for 2018-2019

781

PATIENTS

PARTICIPATED IN RESEARCH ACROSS THESE PRIORITY AREAS



Neuroscience



Cardiology & Cardiac Surgery



Surgical and Medical Innovation



Cancer



Rural & Remote Health



15,338

SAMPLES ADDED TO OUR BIOBANK

Biobank samples contribute to large international projects, including research aiming to:

- Develop a new early diagnostic test for prostate cancer using a urine sample.
- Investigate proteins in the blood that are associated with endometriosis, paving the way for the development of a quick and easy diagnostic test.
- Increase biological knowledge of the autism spectrum and co-occurring conditions to transform the lives of autistic people across the lifespan.

Making a difference



Access to life-changing treatment conducted at our clinical trials centre



I finally found people who truly care about my condition and the challenges we face.

Wendy, Coeliac Disease

A Phase 2 clinical trial for a novel coeliac disease vaccine (Nexvax2®) in which Wesley Medical Research enrolled the highest number of participants globally.



I finally have joy back in my life. The future is bright for me and my family.

Kym, Porphyria

A Phase 3 clinical trial testing a novel gene silencing agent to treat rare, genetic diseases characterised by potentially life-threatening attacks.



Wesley Medical Research saved my life.

Wayne, Pompe Disease

A Phase 3 clinical trial investigating a new generation enzyme replacement therapy for treatment of a progressive, debilitating and often fatal neuromuscular disease called Pompe disease.



116

HIGH IMPACT PUBLICATIONS IN



internationally-recognised

peer-reviewed journals authored by researchers across our four UnitingCare hospitals. Outlined are three key projects.

1

Results from the largest ever study of septic shock, led by Professor Bala Venkatesh | The Wesley Hospital

A research project involving 3800 patients investigated the role of steroids in treating septic shock – a potentially fatal infection. The results of this research have changed international clinical practice by demonstrating that steroids reduce the duration of septic shock and decrease the length of a patient’s hospitalisation, but do not lead to fewer deaths. Venkatesh et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. New England Journal of Medicine, 2018.

2

Optimising use of deep brain stimulation in patients with Parkinson’s disease, led by Dr Philip Mosely | St Andrew’s War Memorial Hospital


While deep brain stimulation (DBS) is an established treatment for Parkinson’s disease that can reduce motor symptoms and improve quality of life, it has been associated with the development of distressing neuropsychiatric side effects. This research provided evidence that the location of the electrodes used to administer DBS plays an important role in determining whether patients will develop neuropsychiatric symptoms. This has the potential to significantly improve safety and tolerability of DBS for patients with Parkinson’s disease. Mosely et al. The Site of Stimulation Moderates Neuropsychiatric Symptoms After Subthalamic Deep Brain Stimulation for Parkinson’s Disease. NeuroImage: Clinical, 2018.

3

Targeting genetic changes to treat multiple sclerosis, conducted by Professor Judith Greer and Professor Pamela McCombe | St Andrew’s War Memorial Hospital


Results from this novel research project showed that a specific genetic change in patients with progressive multiple sclerosis affected how they responded to a treatment agent. These results may play a role in the design of new clinical trials, and help clinicians decide on treatment options for patients with multiple sclerosis. Yan... McCombe, Greer. Increased Constitutive Activation Of NF- B p65 (RelA) in Peripheral Blood Cells of Patients with Progressive Multiple Sclerosis. Journal of Neuroimmunology, 2018.

Translational Research Pathway



\$2,474,244

TOTAL INVESTMENT INTO MISSION





Chairman's report

It is my great pleasure to report on the activities of Wesley Medical Research. Our research continues to serve patients across the four UnitingCare hospitals and has collected a long list of significant achievements over its 24-year history.

In July 2019, Associate Professor John Allan stepped down from the Chief Research Advisor role, a position he has held with great distinction for the past 2 years. He brought invaluable skills, experience and leadership to Wesley Medical Research. He has steered the institute through a period of change and leaves an outstanding legacy.

I would like to take this opportunity to thank two other members of our board whose terms have recently

come to an end: Ms Deborah O'Toole and Mr Richard Lizzio. Along with Associate Professor John Allan, they have made a great contribution to Wesley Medical Research. We have welcomed three new members: Ms Mairi McNeil, Dr John Rivers and Mr Michael Kreig. I would like to acknowledge and thank my fellow board members, members of research committees and dedicated volunteers who give generously of their time and expertise.

Wesley Medical Research has continued to grow in 2018-2019, with the number of participants involved in our research increasing from 428 to 781. I would like to acknowledge the patients who have participated in our research. By taking part in our work you have contributed to advancing scientific knowledge and, in some cases, improving health outcomes for yourself and others. Without your involvement, our research would not be possible.

We want to improve patient outcomes, but this is only possible with the continued support of our donors. I would like to thank our tremendously generous philanthropists, donors, corporate sponsors and community fundraisers. We are grateful for donations of all sizes and thankful for the many people who have chosen to contribute.

I would like to acknowledge our biggest philanthropic donors, Lyn and Bobbie Brazil AO and John and Wendy Thorsen. I would also like to highlight the important and continued support from: Invitro Technology, Vidyajey Foundation, Albrecht Foundation, Mitsubishi Development and The Justin Cameron Cancer Care Foundation.

I am excited by the future direction of the organisation and confident it will continue to accelerate discoveries that translate into improvements in patient care and quality of life.

Peter Allen
Chairman



Our fierce pursuit of robust research will continue to break new ground. We want to improve patient outcomes, but this is only possible with the continued support of our donors.

Peter Allen
Chairman



Chief Research Advisor's report

Each year our researchers continue to push the frontiers of medicine; improving the quality of life for patients and contributing to knowledge globally. This year, we have produced some exceptional results.

Wesley Medical Research was acknowledged as the global leader in recruitment for NexVax2, a coeliac disease vaccine trial. Led by Dr James Daveson and supported by Dr Jennifer Schafer, this significant achievement would not have been possible without their dedication and passion for these patients. Coeliac disease will continue to be a focus for Wesley Medical Research as we try to understand and improve outcomes for these patients.

Professor of Intensive Care Medicine at the University of Queensland and Deputy Director of Intensive Care Medicine at The Wesley Hospital, Professor Bala Vanatesh, worked with our team on a world-wide study focused on adjunctive corticosteroid treatment in critically ill patients with septic shock. Published in the New England Journal of Medicine, his findings were considered one of the top ten most influential findings in 2018 and have modified clinical practice in Australia, as well as in both developed and developing countries around the world.



It has been a great pleasure and privilege to lead this research institute. I am confident the next chapter will be an exciting one for Wesley Medical Research.

Associate Professor John Allan
Chief Research Advisor

Neuropsychiatrist Dr Phil Mosley launched an Australian-first study of medicinal cannabis for the treatment of Tourette's Syndrome. This neurodevelopmental disorder is characterised by multiple involuntary movements and vocalisation tics. There is no cure for Tourette's and no medication that works universally for all individuals without significant adverse effects. As you will read in this annual report, Chris Wright is the first patient to complete the trial and has seen exceptional results. It is hoped this promising research will provide patients with life-changing options (pg 10).

This is my final Chief Research Advisor's report, with my appointment ending in July 2019. I joined the Wesley Medical Research board in 2009 and since that time, I have seen our research help thousands of patients, change clinical

practice and contribute to medical advancement in our UnitingCare hospitals and across the globe.

It has been my very great pleasure and privilege to lead this research institution. I am confident the next chapter will be an exciting one for Wesley Medical Research.

Associate Professor John Allan
Director and Chief Research Advisor



Our impact on Tourette's Syndrome

Hope for better quality of life for Tourette's patients.

After trying a dozen different medications, Chris, a Brisbane man who was diagnosed with debilitating Tourette's Syndrome at age 12, is part of an Australian-first medicinal cannabis trial.

For the past 16 years, the condition has impacted all aspects of Chris' life, including his mental health. This trial has offered Chris more than hope. It's offered a future.

Chris Wright was the first participant to commence treatment on a medicinal cannabis clinical trial to treat his neurological disorder Tourette's Syndrome - a disorder that often has its onset in childhood and is characterised by involuntary movements and vocalisations.

Chris developed Tourette's Syndrome in childhood and despite medication, his condition has persisted. His physical tics include rolling of the eyes and spasms in his shoulders and neck. This has meant that even simple tasks like reading a paperback book has been out of reach.

"The purpose of this clinical trial is to investigate whether medicinal cannabis is a potential therapy for people with Tourette's Syndrome," said Wesley Medical Research lead investigator and neuropsychiatrist Dr Philip Mosley.

At 31, Chris is working full-time in Customer Service in Brisbane and spends his day trying to regulate his tics. "The reprieve I've experienced has been very welcome. I've seen a real change in my life," said Chris.

The medicinal cannabis, developed to pharmaceutical standards, contains a mixture of cannabidiol (CBD) and tetrahydrocannabinol (THC) — two phytocannabinoids derived from the cannabis plant. The trial is being conducted by Wesley Medical Research in Brisbane, with the support of the Lambert Initiative at the University of Sydney. The Lambert Initiative is supplying the drug for this trial.

"Given the public interest in the therapeutic use of cannabis, it is important to conduct rigorous and methodologically-sound research," said Dr Mosley.

Participants in the clinical trial at Wesley Medical Research will complete two 6-week periods of treatment with active drug or placebo. To eliminate bias, neither the participant, nor the investigator will know which treatment participants are receiving until the trial is complete.

"Tourette's has really been a blow to my confidence... my life in general. I'm often in pain and so I often spend my days sleeping and recovering just to do it all again..." said Chris.

"The biggest impact this trial has had on my life so far is that my head movements have almost gone and I have been able to read my first book in 10 years. I don't know if anyone realises what a big deal this is for me. This is life-changing."

Senior Research Manager Dr Jennifer Schafer said that "Our focus is to give people like Chris these opportunities to improve their quality of life. We offer hope and answers through medical research.

"We are fortunate to have dedicated front-line clinicians like Dr Mosley leading this important work and donors who continue to support this valuable research."



Australian-first medicinal cannabis trial



Two 6-week periods of treatment



Evidence to support successful treatment

“There is already early evidence to support the successful treatment of Tourette’s Syndrome with cannabinoids” said Professor Iain McGregor, Academic Director of the Lambert Initiative. “This clinical trial could have a major impact and greatly improve the lives of those living with Tourette’s syndrome.”


This research was made possible through the generosity of our donors and The Brazil Family Foundation.



I don’t know if anyone realises what a big deal this is for me. This is life-changing.

Chris





Our impact on coeliac disease

Thanks to your generous support, Wesley Medical Research is improving the diagnosis and treatment of coeliac disease through a dedicated program of research led by Dr James Daveson

A faster, simpler way of diagnosing coeliac disease

280 patients participated in a clinical trial at Wesley Medical Research to determine the accuracy of a pin-prick method of testing for coeliac disease. One of these patients was Adelaide, who was nine-years-old at the time.

Adelaide's mum, Louise, couldn't be happier after encouraging her daughter to participate in the clinical trial. After taking a drop of blood and waiting ten minutes, the trial helped give Adelaide a clear result.

"Without this initial test, we wouldn't have done an endoscopy and she would not have been diagnosed so early," Adelaide's mother Louise said.

Adelaide's gastroenterologist acknowledged there was already significant damage to her small bowel from undiagnosed coeliac disease. It will take Adelaide 12-18 months to recover from the internal damage she sustained. "And now she is on her way to better health," finished Louise.

Adelaide is not alone. It is estimated that 350,000 Australians have coeliac disease with the majority remaining undiagnosed. The disease can potentially cause damage to multiple parts of the body, not just the bowel. Left untreated, it can increase a person's risk of

developing lymphoma, infertility and osteoporosis.

"The impact of this technology could lead to a simpler, faster diagnosis—an important step in a timely and accurate diagnosis," said lead researcher, Dr James Daveson.

Unlocking the secrets to better understanding and treatment of coeliac disease

Wesley Medical Research was thrilled to participate in a Phase 2 clinical trial of a novel vaccine for coeliac disease, Nexvax2®. The trial was designed to demonstrate protection against inadvertent exposure to gluten.

The only intervention currently available for coeliac disease is a strict, lifelong gluten-free diet. While this can reduce intestinal inflammation, even minute amounts of gluten can still trigger an immune reaction.

"This trial was important to establish a potential treatment beyond that of the gluten-free diet" said lead researcher, Dr James Daveson. "Avoiding gluten is challenging and not always effective."

With 40 participants enrolled in the Nexvax2® study, Wesley Medical Research was the highest recruiting clinical trial site globally.

"We were thrilled to be able to offer so many patients the opportunity to participate in this clinical trial," said Senior Research Manager Dr Jennifer Schafer.

"Patients who participate in clinical trials benefit significantly from an enhanced understanding and management of their medical condition. They also help researchers unlock the secrets to the discovery and development of new treatment options in the future," finished Dr Schafer.



This trial was important to establish a potential treatment beyond that of the gluten-free diet.

Dr James Daveson



Our impact in regional Queensland

Research tackling the growing obesity problem in Emerald, Central Queensland.



34% of Central Queensland adults are obese



Priority areas are obesity and mental health



Building sustainable, healthy habits

Located 900km north-west of Brisbane, Emerald has a population of just over 14,000.

This small community is built upon strong mining and agriculture industries, workforces that traditionally have long hours, higher than average weekly incomes and poorer health outcomes.

Figures show that 34% of Central Queensland adults are obese and coronary heart disease in the region



The resources are focused on building healthy, sustainable habits.

Dr Tamara Street

continues to rise. These alarming statistics led Wesley Medical Research to investigate ways to improve the health of Emerald residents.

Sponsored by Mitsubishi Development Pty Ltd, Adjunct Professor Mary-Louise Fleming (Lead Researcher), Louise Baldwin (Senior Researcher), Dr Tamara Street (Psychologist) and Klaire Somoray (Senior Research Assistant) conducted a six month project in Emerald to co-develop a health promotion report and resource that is regionally relevant, cost effective and innovative.

“Our approach was to engage locally to understand how we could work together to tackle the growing issue,” said Dr Tamara Street.

This project combined evidence from national datasets with local insight and knowledge from health professionals, community leaders and service providers working and living in Emerald.

The workshops identified strengths in the local community that are supporting healthy lifestyles and current barriers. The strained health services in the region were

also acknowledged. In the past 12 months, the community also identified mental health as a significant health priority after losing 18 lives to suicide in the region.

“With strong evidence to suggest that regular exercise may alleviate some symptoms of depression, we hope this toolkit could assist in improving mindsets too,” said Dr Tamara Street.

The “Hey Emerald, Let’s Get Healthy” resource has been developed to assist health promotion planning and implementation. The free resource also includes promotional material suitable for the region.

“The resources are focused on building sustainable healthy habits, instead of ‘quick fix’ solutions. The report outlines a range of recommendations to help build a happier and healthier Emerald” concluded Dr Street. As well as providing access to a range of health promotion assets, the website provides links to local free or low cost programs already available in the Emerald area.

The workshops identified that the leading health priority areas are obesity and mental health.

Research Program

Wesley Medical Research is focused on supporting health areas of concern in contemporary society, including; neuroscience, cardiology and cardiac surgery, cancer, surgical and medical innovations, and remote and rural health.

Our researchers are committed to translating scientific results into clinical applications, making more accurate diagnoses, improved treatments and faster recovery pathways a reality for patients.

Australian and international biomedical researchers. This resource is fundamental in understanding and ultimately finding cures for the most debilitating diseases.

In addition to our research, we operate a world-class biobank which sources, stores and supplies tissue, blood and data for collaboration with



Surgical & Medical Innovation



Cancer



Neuroscience



Cardiology and Cardiac Surgery



Rural & Remote Health



Biobank

Research Projects

2018-2019



CANCER

Lay Title	Scientific Title	Principal Investigator
Repurposing Drugs for Malignant Glioma	A Pilot Study of the Use of Metformin, Atorvastatin and Celecoxib From Presurgery to 9 Months Post Diagnosis in Patients with Malignant Glioma: A Phase 1 Study	Prof David Walker
Comparison of Improved Imaging Techniques to Detect Spread of Cancer in Lymph Nodes in Patients with Prostate Cancer	The MAGNIFI trial: Metastasis Assessment with Gallium-68 PSMA and Nanoparticle Imaging Fusion International	Dr Nicholas Brown



CARDIOLOGY & CARDIAC SURGERY

Lay Title	Scientific Title	Principal Investigator
Does High Intensity Interval Training Lead to Better Outcomes Compared to Moderate Intensity Continuous Exercise in Hospital-Based Cardiac Rehabilitation?	Feasibility, Safety, Adherence and Efficacy of High Intensity Interval Training in Hospital-Based Cardiac Rehabilitation. Is it Superior for Patient Outcomes?	Dr Jenna Taylor
INGEVITY	INGEVITY : Active Fixation and Passive Fixation Pace/ Sense Lead Clinical Study	Dr John Hayes
Predicting Response to a New Treatment for Cardiac Amyloidosis	The Return of the Normal Heart - An MRI Analysis of Resolution of Cardiac Amyloidosis After Chemotherapy and Bone Marrow Transplantation	Dr Ben Fitzgerald



CARDIOLOGY & CARDIAC SURGERY

Lay Title	Scientific Title	Principal Investigator
How Can We Reduce Bleeding and Blood Clotting Risks During and After Transcatheter Aortic Valve Implantation?	Towards the Rational Use of Anti-Thrombotic Prophylaxis to Minimize Thromboembolic and Bleeding Complications Following Transcatheter Aortic Valve Implantation	Dr Jonathon Fanning
Mitral Valve Repair 1991 To 2006 and SAMI-Net Mitral Valve Repair Data Registry	Long Term Results Following Repair for Degenerative Mitral Regurgitation – Analysis of Factors Influencing Durability	Dr Michael Gardner



SURGICAL & MEDICAL INNOVATION

Lay Title	Scientific Title	Principal Investigator
Does Surgery for Obesity Have a Negative Effect on Bone Density?	Effects of Bariatric Surgery on Bone Density at 24 Months	Dr Margaret Williamson
Management of Blood Loss During Total Knee Replacement Surgery	A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty	Dr Sue Clark
Improving Diagnostic Testing for Coeliac Disease	Evaluating the Efficacy of a Point of Care Testing and HLA Typing in Screening High Risk First Degree Relatives of Patients with Coeliac Disease	Dr James Daveson
Nexvax2	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in HLA-DQ2.5+ Adults with Coeliac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge	Dr James Daveson
Speech Performance and Gene Expression In Galactosaemia Patients	FOXP2 Gene Expression in Classic Galactosaemia	Professor David Coman
ADVOCATE	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy Of CCX168 (Avacopan) In Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab Or Cyclophosphamide/ Azathioprine.	Dr Daman Langguth
ENVISION	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicentre Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyria	Professor David Coman



NEUROSCIENCE

Lay Title	Scientific Title	Principal Investigator
A Clinical Trial to Assess the Effectiveness of Tetrahydrocannabinol and Cannabidiol for the Treatment of Tourette's Syndrome	A Randomised, Double Blind, Placebo-controlled, Crossover Trial of Tetrahydrocannabinol and Cannabidiol for the Treatment of Tourette's Syndrome	Dr Philip Mosley
Pilot Study – Exercise Managing Parkinson's disease	A Physiotherapy Exercise Program with a Self-Management Approach to Improve Physical Activity in People with Mild-Moderate Parkinson's Disease: A RCT	Professor Sandra Brauer
Using a Clinically Approved Drug to Block Chronic Inflammation in Parkinson's Disease	Targeting Peripheral Inflammatory Pathology in Parkinson's Disease Using Repurposed Drugs	Dr Richard Gordon
New Treatment for Insomnia In Parkinson's Disease Patients	Using N-of-1 Trials to Identify Responders to Melatonin for Sleep Disturbance In Parkinson's Disease	Dr Jane Nikles
The Queensland Drug Repurposing Initiative (QDRI)	Repurposing of Clinically Approved Drugs for Treatment of Neurodegenerative Diseases	Associate Professor John O'Sullivan and Dr Richard Gordon
New Treatments for Brain Disease	Development and Translation of a Complement C5a Receptor Antagonist to Clinical Trials for Motor Neurone Disease and Huntington's Disease	Associate Professor Trent Woodruff
Investigating the Relationship Between Gene Mutation and New Treatment for Multiple Sclerosis Patients	Does Genetic Variation in Genes Controlling Pro-Inflammatory Immune Responses Modulate Outcomes of MIS416 Treatment in Patients with Multiple Sclerosis?	Associate Professor Judith Greer
Identification of Non-Genetic Causes of Amyotrophic Lateral Sclerosis Including Circulating Toxins	Use of Mass Spectrometry to Identify Circulating Toxins in People with Amyotrophic Lateral Sclerosis (ALS)	Professor Pamela McCombe
Investigating the Mechanism of Energy Breakdown In Motor Neurone Disease (MND) Patients	Assessment of Metabolic Health in Neurodegeneration: Studies in Motor Neurone Disease	Dr Shyuan Ngo



NEUROSCIENCE

Lay Title	Scientific Title	Principal Investigator
Lemtrada PASS	A Prospective, Multicenter, Observational Post-Authorisation Safety Study to Evaluate the Long Term Safety Profile of Lemtrada® (Alemtuzumab) Treatment in Patients with Relapsing Forms of Multiple Sclerosis. Post Authorisation Safety Study (PASS) Protocol	Professor Pamela McCombe
Lemtrada TOPAZ	A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)	Professor Pamela McCombe
Improving Gut Health in Motor Neurone Disease Patients with Squalamine	A Randomised, Controlled Phase 1 Study to Investigate the Safety and Efficacy of Orally Administered Squalamine in Subjects With Motor Neurone Disease	Professor Pamela McCombe
AubPRO	An Observational, Non-Interventional, National Study to Evaluate Quality of Life and Adherence in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Aubagio (Teriflunomide) in Routine Clinical Practice	Dr Noel Saines
ESTEEM	A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)	Professor Pamela McCombe
COMET	A Phase 3 Randomised, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-Naïve Patients With Late Onset Pompe Disease	Associate Professor Robert Henderson
Decide OLE	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Study 205MS301. Amendment 1: Extension of 96 Weeks. Total Duration Now up to 5 Years	Dr Noel Saines
EATT for MND: Exposing Mechanisms of Impaired Appetite Regulation in Motor Neurone Disease	Endocrine and Appetite Targets and Therapies (EATT) for Motor Neurone Disease (MND): Investigating Mechanisms of Impaired Appetite Regulation and Weight Loss in MND	Dr Frederik Steyn



RURAL & REMOTE HEALTH

Lay Title	Scientific Title	Principal Investigator
Healthy Bowen Basin	Local Action for Local Health Education – Laying the Foundation for Improvements in Mental Health, Physical Activity and Healthy Eating in Regional Queensland	Professor Mary-Louise Fleming



Lake Murraboon



Thank you

As a donor, volunteer and advocate we would like to thank you for your continued support.

PATRONS

His Excellency, Paul De Jersey AC
Emeritus Prof John Pearn AO
Mr Martin Albrecht AC
Prof Maurice Webb M.D.

VOLUNTEERS

Dr Terence Frost
Mrs Jocelyn Henry
Mrs Janette McConaghy
Mr Des Olling
Mr Sid Owen
Mr Som Ranga
Mr Malcolm Scott

BEQUEST

Estate of the Late
Lauriet Margaret Hooper

CORPORATE SUPPORTERS

Invitro Technologies
Mitsubishi Development Pty Ltd

TRUSTS AND FOUNDATION

Albrecht Foundation
Borgert Family Endowment
Brazil Family Foundation
Edward Bullock Endowment
Justin Cameron Cancer Care
Foundation

Greatorex Foundation Pty Ltd
Sartain Family Foundation
Stack Family Foundation
Thorsen Family Foundation
Vidyajey Foundation

MAJOR DONORS

Dr James and Mrs Gearty Aylward
Mr John Allpass
AProf John Allan and Dr Janet Allan
Mr Peter and Mrs Anne Allen
Mrs Lynette Barnett
Mr Eddie and Mrs Katherine Codd
Dr Sue Clark
Mr Alexander Dixon
Mrs Dell and Mr Laurie Dunn
Mrs Kay and Dr Jon Douglas AM
Mr John and Mrs Patrice Foote
Mrs Sue and Mr Chris Flook
Mr Troy and Mrs Karelia Gianduzzo
Mr Richard Hughes
Mrs Marie Isackson
Mrs Cathryn Mittelheuser AM
Mr Christopher Morton
Mr David and Mrs Vivien McGarry
Mr Ian and Mrs Penny Moysey
Mr Tom McKerrell
Emeritus Prof Glenda Strachan
and Mr Sid Owen
Mr Alec and Mrs Mary Peden OAM
Mrs Viti Packer
Mr John and Mrs Patsy Quayle
Mrs Bev and Hugh Sheardown AM

Mrs Maureen Stevenson
Mr Russell and Anne Stitz
Mr Rodney Wylie OBE
Mr Bill and Mrs Lorretta Whitmore

REGULAR SUPPORTERS

Mr Peter Billingham
Mr John Clark
Mrs Raelene Cranna
Dr Ben Fitzgerald
Mr Frank Giles
Mrs Virginia Gehrke
Mrs Diane Hollens-Riley
Mrs Sarah Hutton
Mr David McColm
Mr Alex McLean
Mr Rob Ross
Ms Leona Skene
Mrs Helen Wang
Dr Duncan Walker
Mrs Margaret White

DONORS

Mr Dale Anderson
Mr Brad Baker
Ms Leila N. Ball
Mr Colin R. Baxter
Ms Carol Bayley
Ms Nelda Beal
Ms A Bell
Ms Margaret Bell

Thank you

DONORS

Mrs Rosemarie Bell
Mr Peter Bennett
Mr J Blackburne
Mrs Judy Blake
Mr Gordon Bohl
Ms Anna Bonanno
Mr Michael Borgese
Mrs Jill Boughen
Mrs Marita Bowden
Mrs P Bowen
Mr George Bowhay
Mr Ian Broadfoot
Mr Peter Campbell
Mr Peter Carr
Mrs Marie Cassimatis
Mrs Jill Catt
Ms Kym Chalmers
Mrs Jean Clark
Mr Robert Clarke
Mrs Elizabeth Cleave
Mrs Lyn Clements
Mrs Peter Coates
Ms Janette Collins
Mr Bruce Condon
Mr James Coogan
Mr Tony and Mrs Therese Cotter
Mr Peter Cranna
Ms Raelene Cranna
Mr Anthony Cranston
Mrs Betty Cribb
Dr Martin Culwick
Mr Peter Cummiskey

Mr Lex Davidson
Ms Helen Davies
Mr Clifford Dieckmann
Mr Peter and Mr Mary Dimitrios
Ms Tania Dujmovic
Mrs Mary Dwyer
Prof Mervyn Eadie AO
Mrs Bau and Mr Edwin Earle
Ms Susan Edwards
Mr Edgar Faux
Mr Keith Fittock
Dr Colin and Mrs Isobel Furnival
Mrs Glenda and Mr Gary Galway
Mrs Joan Gauci
Mrs Lurline Gedge
Ms Marian Gibney and
Mr Ken MacDonald
Mrs Catherine Gill
Mrs Catherine Gillett
Sandra Gleeson
Mrs Goffage
Mr Col and Mrs Estelle Goldberg
Mrs Vickie Goldsack
Mrs Andrea and Mr Ron Goltz
Mrs Daphne Green
Mr Niklaus Grob
Mr Alan and Mrs Wendy Grummitt
Mr Robert Gunthorpe
Mrs Doris Hamilton-Roberts
Mr Ian and Mrs Leah Harvey
Mr John Hayward
Heart Support Australia Ltd
Caboolture & Districts Branch
Mr Peter Henderson

Mrs Roslyn and Mr Dennis Hinton
Mr Bruce Hohl
Mr Ian Horton
Mr Ernst and Mrs Mary Hug
Dr Wilhelmina Huston and Dr Paul Burrell
Rev. Ted Hutton
Mrs Gail and Mr Lawrie Hynes
Mr Ron Irlam
Mr Bill Irvine and Mrs Joan Irvine
Mr Kevin Jerrard
Mr Grant Kaye
Mr Ian Keilar
Mr Matthew Kelly
Mrs Anne Kenwood
Ms Sharen Kenny and Mr Ian Withnall
Mrs Daphne Kerkin
Mrs Judith Kincade
Mrs Diane King
Mr Paul King
Mrs Valerie King
Ms Maree Klemm
Ms Marianne Klobuchar
Mr Novica Kostic
Mr Koutsoukos
Mr Kevin Kranz
Mrs Judith Kurtz
Mrs Joan Lawrence AM
Ms Tegan Le Page
Mr Donald Leaming
Mr Ray Lewis
Mrs Helen and Mr Noel Lipp
Mr John and Mrs Nancy Logan
Mr John Logan, RFD



Together, we can continue to drive discovery,
give hope and change lives.

Mr Robert Logan
Mr Ian Low
Ms Donna MacCallum
Mrs Doreen MacGowan
Mr Jeff Maclean
Mr Owen and Mrs Sue Maller
Mr Selwyn and Mrs Jocelyn Maller
Mr Peter Marsh
Mrs Gael McAlpine
Mr Lex and Mrs Josephine McAulay
Mrs Brenda McCarthy
Mr David McCole
Mr Ian and Mrs Marjorie McCubbin
Ms Jill McGhie
Mr Andrew and Mrs Debra McNair
Ms Mavis McPherson
Mrs Jan and Mr Kevin McSweeney
Mrs Lynda Mitchell
Mr Tom Moore
Mr and Mrs Mundell
Mr Vince Mungomery
Mr Don and Mrs Jacquelyn Munro
Mrs Patricia Munro
Mr Michael Murphy
Mrs Lorna Murray
Mr Martin Neudert
A/Prof Jim and Mrs Jill Nicklin
Ms Agatha Nucifora
Mr Giuseppe Nucifora
Mrs Jackie Nucifora
Mr William J. Oates
Mr Graeme M. O'Connor
Mr Robert Parker
Parley Presentation Technology

Dr Randal and Dr Lucy Pascoe
Mrs Elwyn Paton
Mr Bruce Paulsen
Mr Don Pickering
Mrs Valmai Pidgeon, AM
Mr John Pitman
Mr Johannes Pronk
Prostate Cancer
Association Townsville
Mr Anthony Prout
Dr Robyn Pugh and Mr Don Keating
Mrs Jocelyn Ranson
Mr Donald Reiman
Mr Andrew Renton
Mrs Ruth Richardson
Mr Peter Robinson
Ms Jasmin Rogers
Ms Leona Romaniuk
Ms Esma Ross
Mr Paul Ross
Mr Colin Rourke
Mrs Myfanwy Rowlands
Ms Beth Sawers
Mr Ian Shallcross
Mr John Sharwood
Ms Karen Shields
Ms Dorothy Singer
Mr Brian and Mrs Judith Smith
Ms Laurel Smith
Ms Janette Snewin
Mr Simon Stahl
Dr Alan and Miriam Stocks
Dr Kate Stringer
Mr Barry and Mrs Judy Sullivan

Mr Alan and Mrs Anne Symons
Mrs Marjorie Tame
Mrs Irene Taylor
Mr Sukhchain Tiyur
Dr Frank Tomlinson
Mr Gray Tovey
Mr Thomas M. Treston
Dr Ross Turner
Mr Jan van der Have and Dr Barbara
Williams
Mrs Mary Vandeleur
Mr and Mrs Varitimos
Dr Petar Vujovic
Mrs Margaret Wallace
Mr John Walton
Prof Emeritus Roy Webb AO and Mrs
Heather Webb
Mr Radley and Mrs Jill West
Mr Brian and Mrs Lynette Wharton
Ms Michele White
Mr Arwen Whiting
Mrs Nerine Whittingham
Mrs Susan C. Wilkes
Mrs Irene Willett
Mrs Edna Winkel
Mr and Mrs Withey
Mr Claude and Mrs Fay Wolski
Mr Allan Wright
Dr John and Mrs Gael Yaxley
Dr Catherine Yelland
Dr Stephen Yelland
Mrs Pina Zappulla



Our Board

The 2018-19 Wesley Medical Research Board, chaired by Mr Peter Allen, consists of skilled and dedicated people who govern the organisation.



MR PETER ALLEN, CHAIRMAN

A Director since 2005, Mr Peter Allen is a former partner in and consultant to national law firm Allens Linklaters and is a Notary Public.



ASSOCIATE PROFESSOR JOHN ALLAN

A/Prof John Allan has been an obstetrician and gynaecologist at The Wesley Hospital since 1984. He is the Chief Academic Medical Officer of UnitingCare Health and Head of the UnitingCare Clinical School.



MR MICHAEL KRIEG

Mr Michael Krieg has over 30 years' experience, commencing his career as a nurse before becoming the General Manager of The Wesley Hospital in 2017. Michael is currently the acting Group Health Executive for UnitingCare Health.



MR CHARLIE SARTAIN

Mr Charlie Sartain joined the Board in 2009. Charlie has more than 30 years of international mining experience. He also a Member of the UQ Senate and Chairman of the Advisory Board of the Sustainable Minerals Institute.



DR IAN DICKINSON

Dr Ian Dickinson has been an orthopaedic surgeon at The Wesley Hospital for over 25 years. He has also served as Chairman of the Queensland Branch of the Australian Orthopaedic Association.



MR PETER CROWLEY

Mr Peter Crowley is a highly experienced business leader and public company director with 15 years of experience leading public companies and 17 years of experience serving on public company boards both in Australia and overseas.



DR CHRISTINE FOLEY

Dr Christine Foley is the Director of Clinical Governance with UnitingCare Health. She worked in senior leadership roles within Catholic health and aged care as a nursing leader and brings her unique perspective.



DR JAMES AYLWARD

Dr James Aylward is an innovative researcher and an active mentor for tech start-ups in health sciences. Dr Aylward was recently awarded the 2018 Clunies Ross Innovation Award for developing Picato, an anti-skin cancer drug.



DR JOHN LUMLEY

Dr John Lumley is a colorectal surgeon practicing at The Wesley Hospital. John has served on the executives of the Gastroenterological Society of Australia, and the Colorectal Society of AU and NZ.



MS MAIRI MCNEIL

Ms Mairi McNeill began as General Manager of St Andrew's War Memorial Hospital in December 2018. Mairi is an experienced healthcare executive who has worked in the private industry for over 23 years.



DR JOHN RIVERS

Dr John Rivers is a practising cardiologist and founding member of the Queensland Cardiovascular Group. John has extensive experience in business development and governance in the healthcare industry.



MS DEBORAH O'TOOLE

Ms Deborah O'Toole has extensive experience and expertise as a Chief Financial Officer for listed companies in a range of industries. She was appointed as QR National's Chief Financial Officer in December 2007 after a career that included 20 years in the mining industry.



PROFESSOR MARY-LOUISE FLEMING

Professor Mary-Louise Fleming is Public Health and Social Work Head of School at the Queensland University of Technology. She brings over 25 years experience in public health and health promotion.



MR RICHARD LIZZIO

Mr Richard Lizzio is the Health, Group Executive for UnitingCare Health. Richard has executive responsibility for four UnitingCare Hospitals.

Managing our resources

FINANCIAL OVERVIEW

We are proud to be a not-for-profit organisation. The 2018-19 surplus allows us to expand our operations to fulfill our mission to give patients better treatment options and improved quality of life for a range of contemporary diseases and health issues.


REVENUE

Total revenue in 2018-19 was \$2.605 million with a significant proportion of revenue coming from fundraising activities and fee-for-service income. The revenue by source is displayed to the right.

FINANCIAL POSITION

As at 30 June 2019, total equity was \$21.8 million. Our assets include an endowment of \$8 million, prepaid lease of \$8 million and the balance held in term deposits, cash and managed investments to fund future mission-related work. As at 30 June, \$2.54 million is allocated to current research programs.

Revenue	2019 (\$)	2018 (\$)
Fundraising income	855,717	1,545,287
UnitingCare support	305,906	355,995
Bequests	100,000	139,440
Investment income	494,148	558,438
Fee for service income	615,916	526,716
Facilities income	101,090	80,149
Other	132,622	224,216
Total	2,605,399	3,430,241





**WESLEY MEDICAL
RESEARCH®**

Level 8, East Wing, The Wesley Hospital
451 Coronation Drive, Auchenflower Q 4066

T 07 3721 1500 **F** 07 3721 1590

wesleyresearch.org.au



©2019 Wesley Medical Research
ABN 85 066 149 666